Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patientsVISANI, Giuseppe; BRECCIA, Massimo; PREGNO, Patrizia et al.American journal of hematology. 2010, Vol 85, Num 12, pp 960-963, issn 0361-8609, 4 p.Article

Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective StudyLATAGLIATA, Roberto; FERRERO, Dario; TIRIBELLI, Mario et al.Drugs & aging. 2013, Vol 30, Num 8, pp 629-637, issn 1170-229X, 9 p.Article

Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantationLEONI, Franco; GIANFALDONI, Giacomo; ANNUNZIATA, Mario et al.Haematologica (Roma). 2002, Vol 87, Num 5, pp 485-489, issn 0390-6078Article

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinibBRECCIA, Massimo; LATAGLIATA, Roberto; PREGNO, Patrizia et al.Haematologica (Roma). 2011, Vol 96, Num 10, pp 1457-1461, issn 0390-6078, 5 p.Article

Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemiaSCHIAVONE, Ettore Mariano; DE SIMONE, Mariacarla; PALMIERI, Salvatore et al.European journal of haematology. 2003, Vol 71, Num 1, pp 23-28, issn 0902-4441, 6 p.Article

High-dose cytarabine as consolidation treatment for patients with acute myeloid leukemia with t(8;21)PALMIERI, Salvatore; SEBASTIO, Lucia; FERRARA, Felicetto et al.Leukemia research. 2002, Vol 26, Num 6, pp 539-543, issn 0145-2126Article

Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsing after first complete remissionFERRARA, Felicetto; MORABITO, Fortunato; LEONI, Franco et al.Haematologica (Roma). 2001, Vol 86, Num 8, pp 814-820, issn 0390-6078Article